AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$IQV

Berkshire James G. sold $697K of IQV

Berkshire James G. (See Remarks) sold 2,668 shares of IQVIA HOLDINGS INC. (IQV) at $261.33 ($0.70M total) on 2026-09-02.

Original reporting
SEC EDGAR · Berkshire James G.
Published Sep 4, 2026, 9:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 10:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$IQV
Bearish
medium confidence
Mentioned
$IQV
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IQVBearishLow
01

Why it matters

The disclosed sale is the first public report of this transaction, making it a primary source.

02

Market read

Small insider sale; limited trading impact but worth noting for short-term sentiment.

03

What to watch

No disclosed 10b5‑1 plan; insider may have personal liquidity needs.

Relevance 5/10Novelty 4/10Timing: filed Sep 4, 2026

Background

Form 4 filings disclose insider transactions; traders monitor them for sentiment cues.

Company-level read

Ticker impact

$IQVBearishMedium confidence
Context

Officer James G. Berkshire sold 2,668 shares of IQVIA for $697,228, reducing his stake to 10,890 shares.

Expected impact

Modest downward pressure; price may dip 1‑2% in the next trading session.

Evidence & confidence

Sale size is modest relative to market cap, but insider sales often attract short-term traders.

Market effects

Sector

Minimal impact on healthcare data analytics sector.

Regional

U.S. market only.

Global

Low

Counterpoint

What could challenge this read

The sale could be routine portfolio rebalancing, not a negative signal.

Key entities

  • Company
    IQVIA Holdings Inc.

    Provider of health information technology and data analytics.

  • Officer
    James G. Berkshire

    Company officer who sold shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

IQV insider trading history →

Related articles

$IQVHighAI 8/10

5 revealing analyst questions from IQVIA’s Q3 earnings call

IQVIA reported Q3 revenue of $4.43 billion, beating estimates by 1.5%, with adjusted EPS of $3.34, a 2% beat. The company raised full-year revenue guidance to $17.43 billion. Analysts discussed AI-driven workflows, margin improvements, and clinical bookings during the earnings call. CEO Ari Bousbib highlighted proprietary data and life sciences expertise as key differentiators.

finance.yahoo.com
$IQVMedAI 8/10

IQVIA Holdings Inc (IQV) (Q3 2026) Earnings Call Highlights: Record Bookings, Raised

IQVIA Holdings Inc. reported Q3 2026 earnings with record bookings and raised guidance. Revenue was $4.428B, up 8% YoY, and adjusted EBITDA rose 8.7%. Challenges include FX headwinds and R&D backlog adjustments. Management highlighted AI adoption and strong biotech demand. Full-year 2026 guidance was increased, with revenue expected between $17.35B-$17.5B. No 2027 guidance was provided.

finance.yahoo.com
$IQVHighAI 8/10

What IQVIA (IQV) Said on Its Q3 Earnings Call

IQVIA reported Q3 revenue growth of 6.9% to $1.79B, with organic growth at 4%. AI adoption contributed to commercial and clinical momentum, with 415 AI agents deployed. The company raised its 2026 outlook, expecting revenue of $17.35B-$17.50B and adjusted EPS of $12.90-$13.00. Cash flow from operations was $825M, with free cash flow at $667M.

finance.yahoo.com
$IQVHighAI 9/10

IQVIA (IQV) Q3 2026 Earnings Call Transcript

IQVIA reported Q3 2026 revenue of $4.43B, up 8%, with organic growth at 6%. Adjusted EBITDA grew 8.7% to $1.03B, and adjusted EPS rose 11.3% to $3.34. R&D solutions revenue increased 8.7%, and commercial solutions revenue grew 6.9%. The company raised full-year revenue guidance to $17.35B-$17.5B. AI deployments and emerging biopharma funding growth were highlighted.

fool.com